Free Newsletter
Merck's Gardasil protects against strains not in vax
Two new studies to be published in the April 1 issue of Journal of Infectious Diseases say Merck's quadrivalent human papillomavirus vaccine, Gardasil, appears to protect against viral strains not included in the vax. This is especially the case for women not exposed to the virus before vaccination, American Medical News reports.
The analysis were based on data on 17,622 women, aged 16 to 26, taking part in Phase III studies for Gardasil. One study showed that Gardasil reduced the risk of precancerous changes in cervical cell growth caused by 10 strains not included in the vaccine in women unexposed to the virus. The second paper reports that when both the exposed and unexposed groups were analyzed together, the risk was cut by 15.1 percent.
Study authors say it's not completely clear why Gardasil protects against strains not included in the vaccine and questions still remain about the duration of immunity. "There are families of related HPV types, and we think the antibodies made when women are vaccinated have an effect against other closely related viral types," said Dr. Brown, the lead author on the first paper and a co-author on the second.
- check out the AMNews article for more
Related Articles:
FDA delays Gardasil for older women
What's stopping girls from getting the HPV jab?
Critics accuse Merck of hyping cervical cancer risk
Study examines cost-effectiveness of Gardasil
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




